Tiospirone

Tiospirone

SCHEMBL29356145

O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tiospirone SCHEMBL78696 1.00
Tiospirone SCHEMBL122406 0.99
SCHEMBL13532488 0.99
Tiospirone SCHEMBL11081111 0.98
SCHEMBL10471393 0.90 HTR1A (0.64)
SCHEMBL11077375 0.88 HTR1A (0.69)
SCHEMBL10520426 0.86
SCHEMBL10471021 0.86 HTR1A (0.61)
SCHEMBL11075546 0.86 HTR1A (0.66)
SCHEMBL9413636 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3706762-B1 N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO UNIV EMORY (US) 2024-10-16 EP claimed
EP-1931320-B1 MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME FLAMEL IRELAND LTD (IE) 2022-06-15 EP claimed
US-20260124226-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO UNIV EMORY (US) 2026-05-07 US disclosed
US-20260102422-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO UNIV EMORY (US) 2026-04-16 US disclosed
US-20260077139-A1 SPACER DEVICE WITH FLOW RATE SPIROMETER AEROVU TECHNOLOGIES, INC. (US) 2026-03-19 US disclosed
EP-4705284-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO Emory University (US) 2026-03-11 EP disclosed
US-12551497-B2 N4-hydroxycytidine and derivatives and anti-viral uses related thereto EMORY UNIVERSITY (US) 2026-02-17 US disclosed
US-12521426-B2 Methods and compositions for inhibiting glyoxalase 1 (GLO1) PALMER ABRAHAM (US) 2026-01-13 US disclosed
US-12514993-B2 Spacer device with flow rate spirometer AEROVU TECHNOLOGIES, INC. (US) 2026-01-06 US disclosed
WO-2025235664-A1 PURINE NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2025-11-13 WO disclosed
US-20250339374-A1 BONDED MICROPARTICULATES PREPARATION AND APPLICATIONS THEREOF VENKOR CORP (US) 2025-11-06 US disclosed
US-11331331-B2 N4-hydroxycytidine and derivatives and anti-viral uses related thereto EMORY UNIVERSITY (US) 2022-05-17 US disclosed
EP-3194033-B1 SPACER DEVICE WITH FLOW RATE SPIROMETER AEROVU TECH INC (US) 2022-05-04 EP disclosed
US-11278595-B2 Peptides comprising non-natural amino acids and methods of making and using the same LONGEVITY BIOTECH, INC. (US) 2022-03-22 US disclosed
US-11274158-B2 Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2022-03-15 US disclosed
US-20220062194-A1 Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors OMEROS CORP (US) 2022-03-03 US disclosed
US-11241420-B2 Compositions and methods for prophylaxis and treatment of addictions OMEROS CORPORATION (US) 2022-02-08 US disclosed
US-11236053-B2 NADPH oxidase inhibitors and uses thereof EMORY UNIVERSITY (US) 2022-02-01 US disclosed
EP-3941916-A1 PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO Emory University (US) 2022-01-26 EP disclosed
EP-2286797-B2 Dry powder composition comprising co-jet milled particles for pulmonary inhalation VECTURA LTD (GB) 2022-01-26 EP disclosed